EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[Colorectal neuroendocrine tumor. Rectal carcinoid. ´ëÀåÁ÷Àå ½Å°æ³»ºÐºñÁ¾¾ç. Á÷Àå À¯¾ÏÁ¾] - ðû

[¾Ë¸²]

2023³â 3¿ù 26ÀÏ ³»½Ã°æÇÐȸ KSGE ¼¼¹Ì³ª¿¡¼­ Á÷Àå NETÀÇ Äڵ忡 ´ëÇÑ ÁúÀÇ ÀÀ´äÀÌ ¿©·¯¹ø ÀÖ¾ú´Âµ¥ ¸ðµÎ C code¸¦ ÁÖ°í ÀÖ´Ù°í Çϼ̽À´Ï´Ù. ÄÚµå´Â °è¼Ó ¹Ù²ò´Ï´Ù. EndoTODAY¿¡ ÀÇÁ¸ÇϽÃÁö ¸¶½Ã°í ½ÉÆò¿ø¿¡ Á÷Á¢ ¹®ÀÇÇÏ¿© È®ÀÎÇÏ½Ç °ÍÀ» ±ÇÇÕ´Ï´Ù.

1. ³»½Ã°æ Ä¡·á

2. ³»½Ã°æ Ä¡·á ÈÄ ¾î¶² ȯÀÚ¿¡¼­ ¼ö¼úÀ» ±ÇÇØ¾ß Çϴ°¡?

3. Rectal neuroendocrine carcinoma

4. Cases

5. FAQs

6. References


1. ³»½Ã°æ Ä¡·á Endoscopic treatment

Simple EMR ºÎÅÍ ESD ±îÁö ´Ù¾çÇÑ ¹æ¹ýÀÌ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

EMR for rectal carcinoid

0.3cm W/D neuroendocrine tumor (carcinoid)

Synaptophysin

2019-12-10 ³»½Ã°æÇÐȸ Áý´ãȸ¿¡¼­ ¾Æ»êº´¿ø¿¡¼­ anchor¸¦ ÀÌ¿ëÇÑ EMR¹ýÀ¸·Î EMR-C ¹ýº¸´Ù ºü¸£°í ¾ÈÀüÇÏ°Ô Ä¡·áÇÏ¿´´Ù°í º¸°íÇÏ¿´½À´Ï´Ù.

2022³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ Á¦1ȸ Webinar topicÀÌ Á÷Àå½Å°æ³»ºÐºñÁ¾¾çÀ̾ú½À´Ï´Ù. º¯Á¤½Ä ±³¼ö´ÔÀÇ ¸ÚÁø °­ÀǸ¦ ¼Ò°³ÇÕ´Ï´Ù.


2. [IDEN 2015] ³»½Ã°æ Ä¡·á ÈÄ ¾î¶² ȯÀÚ¿¡¼­ ¼ö¼úÀ» ±ÇÇØ¾ß Çϴ°¡? (°è¸í´ëÇб³ ±èÀº¼ö ¼±»ý´Ô °­ÀÇ)

°è¸í´ëÇб³ÀÇ ±èÀº¼ö ¼±»ý´ÔÀº screeningÀ» Çϸé 10 mm ÀÌÇÏÀÇ rectal NE tumorÀÇ ºñÀ²ÀÌ ÇöÀúÈ÷ ³ô¾ÆÁø´Ù´Â À̾߱â·Î °­ÀǸ¦ ½ÃÀÛÇϼ̽À´Ï´Ù.

Endoscopy 2009

³»½Ã°æÀû Ä¡·á¹æ¹ýÀº ´Ù¾çÇѵ¥ ESD¿Í modified EMRÀÇ ¼ºÀûÀÌ ºñ½ÁÇÏ´Ù´Â Á¡À» ÀçÄ¡ÀÖ´Â ½½¶óÀ̵å·Î ½±°Ô º¸¿©Áּ̽À´Ï´Ù. µ¿°æ¾Ï¼¾ÅÍÀÇ ÀϺ»ÀÎ ÀÇ»ç´Â rectal carcinoid¸¦ ESDÇÒ ÇÊ¿ä°¡ ¾ø´Ù°í comment ÇÏ¿´½À´Ï´Ù.

NCCN guideline (2015)¿¡¼­´Â "<1cm, No follow-up reguired"·Î µÇ¾î ÀÖ°í, ¿¬¼¼´ë ¿¬±¸(Kim DH. Digest Dis Sci 2014)¿¡µµ À§ÇèÀÎÀÚ°¡ ¾ø´Â ȯÀÚ¿¡¼­ intensive surveillance°¡ ÇÊ¿äÇÏÁö ¾Ê´Ù°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.

±èÀº¼ö ¼±»ý´ÔÀº 5 mm grade 1 rectal NE tumorÀÇ EMR Á¶Á÷¿¡¼­ lymphatic invasionÀÌ ÀÖ¾î ¼ö¼úÀ» ±ÇÇÏ¿´°í local lymph node metastasis°¡ ÀÖ¾ú´ø Áõ·Ê¸¦ ¼Ò°³Çϼ̽À´Ï´Ù. ¼­¿ï¾Æ»êº´¿ø¿¡¼­´Â Á÷Àå À¯¾ÏÁ¾ ³»½Ã°æÄ¡·á ÈÄ Á÷Àå¿· ¸²ÇÁÀýÀÌ ÃµÃµÈ÷ (7³â) Ä¿Áø °ÍÀ» ¹ß°ßÇÏ°í ¼ö¼úÇϱ⵵ Çß½À´Ï´Ù (Kim SH. Intest Res 2015). Áï ÀüÀÌ°¡ À־ ¸Å¿ì õõÈ÷ ÀÚ¶õ´Ù´Â °ÍÀÔ´Ï´Ù.

Á÷Àå ½Å°æ³»ºÐºñÁ¾¾çÀÇ Å©±â°¡ ÀÛ´õ¶óµµ lymphovascular invasionÀÌ ÀÖÀ¸¸é ¸²ÇÁÀý ÀüÀÌÀÇ °¡´É¼ºÀº ¾ÆÁÖ ³ô½À´Ï´Ù. 2022³â Gut and Liver Áö¿¡ ½Ç¸° ±¹³» ¿¬±¸¿¡ ÀÇÇÏ¸é ¾à 48.8%¶ó°í ÇÕ´Ï´Ù.

°í¹ÎÀÌ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ³»½Ã°æÀ¸·Î Àß ÀýÁ¦µÈ 1 cm ÀÌÇÏÀÇ ÀÛÀº À¯¾ÏÁ¾ÀÇ º´¸®°Ë»ç¿¡¼­ À§ÇèÀÎÀÚ°¡ ¾øÀ¸¸é ÃßÀû°üÂûÀ» ÇÏÁö ¸»ÀÚ´Â °¡À̵å¶óÀΰú ¿¬±¸°¡ °è¼Ó ¹ßÇ¥µÇ°í ÀÖ½À´Ï´Ù. ±×·±µ¥ ÃßÀû°üÂû ´ë»óÀÌ ¾Æ´Ñ ȯÀÚ¿¡¼­ °£È¤ ÀüÀÌ(metastasis)°¡ ¹ß°ßµË´Ï´Ù. 5³â ÀÌÈÄ¿¡ ¹ß°ßµÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. µµ´ëü ´©±¸¸¦ ¾ðÁ¦±îÁö ÃßÀû°üÂû ÇÏ¿©¾ß ÇÒ±î¿ä? 1¸íµµ ³õÄ¡Áö ¾ÊÀ¸·Á¸é ³Ê¹« ¸¹Àº »ç¶÷ÀÌ ³Ê¹« ¸¹Àº °Ë»ç¸¦ ¹Þ¾Æ¾ß ÇÕ´Ï´Ù. Risk benefit ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù°í »ý°¢µË´Ï´Ù. ¾ÆÁ÷ ¸íÈ®È÷ Á¤¸®µÇÁö ¸øÇÑ À̽´ÀÔ´Ï´Ù.


3. Rectal neuroendocrine carcinoma

°Ç°­°ËÁø¿¡¼­ ÇϺÎÁ÷Àå, anus¿¡ ¿¬ÇÑ neuroendocrine tumor°¡ ¹ß°ßµÇ¾î ¼ö¼úÇÑ È¯ÀÚÀÔ´Ï´Ù. ´ë´ÜÇÑ ½Ç·ÂÀ» °¡Áø Àǻ縦 ¸¸³ª »ý¸íÀ» °ÇÁø ¿î ÁÁÀº ȯÀÚÀ̽ʴϴÙ.


Rectum and anus, abdominoperineal resection: Neuroendocrine carcinoma (G3)
1. Name of Procedure: Abdominoperianal resection
2. Site of Tumor: Rectum
3. Diagnosis: Neuroendocrine tumor
4. WHO classification(2010): Neuroendocrine carcinoma (G3)
5. Multiplicity: Single
6. Size: 1.5x1 cm
7. Extent: Proper Muscle
8. Grading: Mitotic Count: >20/10HPF, Ki-67 labeling index : G3>20%
9. Immunohistochemical Stains: 1. Synaptophysin : Positive, 2. Chromogranin A: Negative, CD56 (+)
10. Lymphovascular invasion: Present
11. Perineural invasion: Present
12. Lymph node metastasis: Number of positive nodes/Total number of nodes(0/16)
13. Resection Margins: Negative
14. Other pathologic components: Hyperplastic polyp


Á¦°¡ ¿ì¿¬È÷ ÃßÀû°Ë»ç¸¦ ÇÏ¿´´ø ȯÀÚÀÔ´Ï´Ù. ¼ö³â Àü rectal carcinoid·Î ÀÇ·ÚµÈ ºÐÀ¸·Î ESD°¡ ½ÃÇàµÇ¾ú½À´Ï´Ù. ´ç½Ã liftingÀÌ µÇÁö ¾Ê¾Æ ½Ã¼úÀÌ ¾î·Á¿üÀ» °Í °°½À´Ï´Ù. ¿©ÇÏÆ° ¿ÏÀü ÀýÁ¦°¡ µÇ¾ú½À´Ï´Ù.

ESD º´¸®°á°ú´Â ¾Æ·¡¿Í °°¾Ò½À´Ï´Ù. Carcinoma¿´°í ±í¾ú°í lymphatic invasionÀÌ ÀÖ¾ú½À´Ï´Ù.

1. Name of Procedure: EMR/ESD
2. Site of Tumor: Rectum
3. Diagnosis: Neuroendocrine tumor (Well-differentiated neuroendocrine carcinoma)
4. WHO classification(2004): Well-differentiated neuroendocrine carcinoma
5. Multiplicity: Single
6. Size: 1x0.9 cm
7. Extent: Proper Muscle
8. pT Stage(AJCC): T2
9. Grading: Mitotic Count(/HPF): 0-1, Ki-67 labeling index: G2 3-20 %
10. Lymphovascular invasion: Present
11. Perineural invasion: Not identified
12. Resection Margins: Positive deep resection margin
. D2-40: Endolymphatic emboli are present
. Ki-67: Positive (3 %)
. Chromogranin: Positive
. Synaptophysin: Positive

¼ö¼úÀ» ½ÃÇàÇÏ¿´°í µÎ °³ÀÇ perirectal lymph node ÀüÀÌ°¡ ÀÖ¾ú½À´Ï´Ù.


¸î ³â ÈÄ Á¦°¡ ÃßÀû ³»½Ã°æÀ» ÇÏ¿´½À´Ï´Ù. Sigmoidoscopy¿´½À´Ï´Ù.

È­¸é ÁÂÃøÀÌ Á¤»ó lumenÀ̵¥ È­¸é ¿ìÃø 1½Ã ¹æÇâ¿¡ ¶Ç´Ù¸¥ lumenÀÌ ÀÖ¾ú°í blind end¿´½À´Ï´Ù. ¹«½¼ pouch¶ó´Â ´À³¦ÀÌ µé¾ú½À´Ï´Ù. ¿Ü°ú ¼±»ý´Ô²² ¹®ÀÇÇÏ¿´½À´Ï´Ù.

Á¦°¡ ¿À´Ã Á÷Àå°æ °Ë»ç¸¦ ÇÑ ¸í ÇÏ¿´½À´Ï´Ù. Rectal neuroendocrine carcinoma·Î ¼ö¼úÇÑ È¯ÀÚÀÔ´Ï´Ù. Á÷Àå°æÀ» Ç×¹® »ó¹æÀ¸·Î ÁøÀÔÇÏ¿´À» ¶§ È­¸éÀÇ ÁÂÃø¿¡ Á¤»ó lumenÀÌ ÀÖ°í È­¸éÀÇ ¿ìÃø¿¡ pouch°¡ ÀÖ¾ú½À´Ï´Ù. PouchÀÇ ³¡Àº blind end ¿´½À´Ï´Ù. ±×·±µ¥ ¼ö¼ú±â·ÏÀ» º¸´Ï... ¼ö¼ú¸íÀÌ "Low Ant.Resection, Ileostomy"¶ó°í¸¸ ¾º¿©ÀÖ°í ¾îµð¿¡¼­µµ pouch¸¦ ¸¸µé¾ú´Ù´Â À̾߱Ⱑ ¾ø¾ú½À´Ï´Ù. À§¾Ï Àü¹® ³»°ú ÀÇ»ç·Î¼­´Â ¼ö¼ú ³»¿ëÀ» ÀÌÇØÇϱ⠾î·Á¿ü°í °æÇèÀÌ ºÎÁ·ÇÑ Àǻ簡 pouchÂÊÀ¸·Î ³»½Ã°æÀ» ¹Ð¾î³Ö´Ùº¸¸é õ°øµµ »ý±æ ¼ö ÀÖ°Ú´Ù ½Í¾ú½À´Ï´Ù. ÀÌ È¯ÀÚ¿¡ ´ëÇÑ ÀÇ°ßÀ» ºÎŹµå¸³´Ï´Ù. ¼ö¼ú ³»¿ëÀ» Á» ´õ Àß ½áÁÙ ¼ö´Â ¾ø´ÂÁö...

¿Ü°ú ¼±»ý´Ô²²¼­ Ä£ÀýÇÏ°Ô ´äº¯À» º¸³»Áּ̽À´Ï´Ù. ±×¸²°ú ÇÔ²²...

Áú¹®/ÀÇ°ß Áּż­ °¨»çÇÕ´Ï´Ù. ȯÀÚÀÇ ³»½Ã°æ »çÁø ¹× ¼ö¼ú±â·ÏÀ» È®ÀÎÇÏ¿´½À´Ï´Ù. ¼ö¼ú ±â·ÏÀÇ "¼ö¼ú¹æ¹ý → anastomosis → method" ºÎºÐÀ» º¸¸é side-to-end ¶ó°í µÇ¾îÀÖ½À´Ï´Ù. ³»°ú ¼±»ý´Ô²²¼­ ÀÌ ºÎºÐ±îÁö È®ÀÎÇϱâ´Â ¾î·Á¿ì¼ÌÀ¸¸®¶ó »ý°¢µË´Ï´Ù.
Anastomosis:
    Circular stapler(name : EEA) (size : 28mm)
    Method :Side-to-end
    Level of anastomosis : 1§¯ from anal verge
    Leakage test : No
Â÷¼¼´ë EMRÀÌ µÇ¸é Á»´õ º¸±â ÁÁ°Ô º¯ÇÒ °ÍÀÔ´Ï´Ù. ±× ¶§±îÁö´Â ¼ö¼ú±â·ÏÁö¿¡¼­ ¼ö¼ú¹æ¹ý → Anstomosis ºÎºÐÀ» Âü°íÇØÁÖ½Ã¸é »ç°í ¿¹¹æ¿¡ µµ¿òÀÌ µÉ °Í °°½À´Ï´Ù. Âü°íÇϽõµ·Ï ±×¸²À» ±×·Áº¸¾Ò½À´Ï´Ù.

¿Ü°ú ¼±»ý´Ô²²¼­ ±×¸²±îÁö ±×·Á¼­ Ä£ÀýÈ÷ ¼³¸íÇØÁÖ½Ã´Ï ½±°Ô ÀÌÇØÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. ȯÀÚ°¡ ¾î¶² ¼ö¼úÀ» ¹Þ¾Ò´ÂÁö Á¤È®È÷ ¾Ë°í ³»½Ã°æ °Ë»ç¸¦ Çؾ߰ڽÀ´Ï´Ù. ¹Ù¸¥ ³»½Ã°æÀÌ ¾ÈÀüÇÑ ³»½Ã°æÀÔ´Ï´Ù.


[Cases]

[Áõ·Ê 1] Rectal neuroendocrine carcinoma with liver metastasis

°ÇÁø º¹ºÎ ÃÊÀ½ÆÄ¿¡¼­ °£ Á¾¾çÀÌ ¹ß°ßµÇ¾î ÀÇ·ÚµÈ ºÐÀÔ´Ï´Ù. MRI¿¡¼­´Â epithelial hemangioendothelioma ¾Æ´Ñ°¡ ÃßÁ¤ÇÏ¿´Áö¸¸ °£ Á¶Á÷°Ë»ç´Â neuroendocrine carcinoma·Î, Á÷Àå Á¾¾ç Á¶Á÷°Ë»ç´Â neuroendocrine carcinoma with lymphatic tumor emboli, Chromogranin (+, focal), Synaptophysine (+, diffuse)·Î ³ª¿Ô½À´Ï´Ù. ȯÀÚ´Â flushing°ú pruritus Áõ»óÀÌ ÀÖ¾ú½À´Ï´Ù. Octreotide IMÀ¸·Î Ä¡·áÇÏ¿´°í Áõ»óÀº ´Ù¼Ò È£ÀüµÇ¾ú½À´Ï´Ù.


[Áõ·Ê 2] Rectal carcinoid with lymph node metastasis

Rectal carcinoid·Î ÀÇ·ÚµÈ È¯ÀÚÀÔ´Ï´Ù.

ESD°¡ ½ÃÇàµÇ¾ú°í º´¸®¼Ò°ß¿¡¼­ lymphatic invasionÀÌ ÀǽɵǾú½À´Ï´Ù.


Well differentiated neuroendocrine tumor (CARCINOID) (G1)
1) size: 1.2x1.0 cm
2) confined to mucosa and submucosa
3) mitosis: 1/10 HPF
4) lymphovascular invasion: suspicious (in one focus)
5) perineural invasion: absent
6) focal involvement of deep cauterized resection margin

¼ö¼úÀ» ½ÃÇàÇÏ¿´°í ¾Æ·¡ÀÇ °á°ú¿´½À´Ï´Ù.

Rectum, low anterior resection : Status post endoscopic submucosal dissection for well-differentiated neuroendocrine tumor
. No residual tumor
. Histologic type and grade: not identified (no residual tumor):
1. Location: rectum
2. Gross type: scar
3. Size: cannot be determined (no residual tumor)
4. Depth of invasion: cannot be determined (no residual tumor)
5. Resection margin: free from carcinoma (no residual tumor) safety margin: proximal, 9.2 cm; distal, 0.5 cm; circumferential (radial), >10 mm
6. Lymphovascular invasion: cannot be determined (no residual tumor)
7. Perineural invasion: cannot be determined (no residual tumor)
8. Regional lymph node metastasis: metastasis to 1 out of 12 regional lymph nodes (1/12: perirectal, 1/12)

Á÷Àå À¯¾ÏÁ¾ ³»½Ã°æ Ä¡·á¿¡¼­´Â º´¸®°ú ¼±»ý´ÔÀÌ ¸Å¿ì ¸Å¿ì ¸Å¿ì ¸Å¿ì Áß¿äÇÕ´Ï´Ù.


[Áõ·Ê 3]

´ëÇÑÀ忬±¸ÇÐȸ ±³À°ÀÚ·á·Î rectal carcinoid with liver metastasis Áõ·Ê°¡ ¼Ò°³µÇ¾ú½À´Ï´Ù.


[FAQ]

[2016-7-1. ¾Öµ¶ÀÚ Áú¹®]

Áú¹® 1. ´ëÀå ³»½Ã°æÁß Rectal carcinoid ·Î 1cm ÀÌÇÏÀÎ °æ¿ì abd' CT µî study ¸¦ ´Ù ÁøÇàÇØ¾ß µÇ³ª¿ä??

Áú¹® 2. rectal carcinoid <1cm (°ÅÀÇ 5mm Á¤µµ size) ¸¦ EMR ·Î Á¦°Å½Ã resection margin ÀÌ positive ÀÎ °æ¿ì ¾îÂîÇØ¾ß Çϳª¿ä?

[2016-7-3. ±èÀº¶õ ±³¼ö´Ô ´äº¯]

Áú¹® 1¿¡ ´ëÇÑ ´äº¯: Rectal carcinoid tumorÀÇ Å©±â°¡ 1 cm ¹Ì¸¸À̸鼭 ±ÙÀ°Ãþ ħ¹üÀÌ ¾ø°í, Á¶Á÷ÇÐÀûÀ¸·Î ¾Ç¼ºµµ°¡ ³ôÁö ¾ÊÀº °æ¿ì ÁÖº¯ ¸²ÇÁÀý ÀüÀ̳ª °£ÀüÀ̵îÀÇ °¡´É¼ºÀº ¸Å¿ì ³·½À´Ï´Ù. ±×·¯³ª µå¹°°Ô Áõ·Êº¸°í°¡ ÀÖÀ¸¹Ç·Î CT °Ë»ç¸¦ ÇØ º¸´Â °ÍÀº ÁÁ°Ú½À´Ï´Ù.

Áú¹® 2¿¡ ´ëÇÑ ´äº¯: ´ëÀåÀÇ °æ¿ì Á¶Á÷ÀÌ ¾ã¾Æ¼­ hot snaring polypectomyµîÀ» ½ÃÇàÇÒ¶§ burning effect·Î ÀÎÇØ resection margin (+)·Î ³ª¿À´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ °ÍÀº ½Ã¼úÀÚÀÇ ÆÇ´ÜÀÔ´Ï´Ù. ½Ã¼úÀÚ°¡ ¿ÏÀü ÀýÁ¦Çß´Ù°í ÆÇ´ÜÇÏ¿´´Ù¸é Á¶Á÷°Ë»ç¿¡¼­ RM (+)·Î ³ª¿Íµµ Å©°Ô ¿°·ÁÇÏÁö ¾Ê¾Æµµ µÉ °Í °°½À´Ï´Ù. ´Ù¸¸, ½Ã¼úÀÚ°¡ ÆÇ´ÜÇϱ⿡ ¿ÏÀüÀýÁ¦µÈ °Í °°Áö ¾Ê´Ù¸é, °¡Àå ÁÁÀº °ÍÀº ±× ºÎÀ§¸¦ Çѹø ´õ ESD·Î ÀýÁ¦ÇØ ÁÖ´Â °ÍÀÌ°í, °ÅÀÇ ÀýÁ¦µÈ °Í °°Àºµ¥ È®½ÅÀÌ ¾ø´Â °æ¿ì´Â short-term follow upÇϼŵµ µÉ °Í °°½À´Ï´Ù.


[2017-9-1. ¾Öµ¶ÀÚ Áú¹®]

¾È³çÇϼ¼¿ä. À̹ø¿¡ ´ëÀå³»½Ã°æÀ» ÇÏ´Ù°¡ Á÷Àå À¯¾ÏÁ¾ ȯÀÚ°¡ À־ Áú¹® ¸ÞÀÏ µå¸³´Ï´Ù. Å©±â´Â 0.7cmÁ¤µµ¿´°í, EMR·Î Á¦°ÅÇÏ¿´°í, Á¶Á÷°Ë»ç °á°ú À¯¾ÏÁ¾, Ç÷°üÀ̳ª ¸²ÇÁÀý ħ¹üÀº ¾ø¾ú°í, CT¿¡¼­ ŸÀå±â ÀüÀÌ´Â ¾ø¾ú½À´Ï´Ù. ±×¸®°í mitotic count¿Í Ki67¿¡¼­ G1ÀÌ¿´½À´Ï´Ù. ÀÌ È¯ÀÚ¸¦ ¾ÏÀ¸·Î ÇÏ°í »êÁ¤Æ¯·Ê¸¦ ÇؾßÇÏ´ÂÁö¿ä? ±×¸®°í, º¸Çè°ø´Ü¿¡ ÀüÈ­Çؼ­ ¹°¾îº¸´Ï À¯¾ÏÁ¾ Äڵ尡 ¾ø´Ù°íÇؼ­ ´çȲÇß½À´Ï´Ù. ¼±»ý´ÔÀº Äڵ带 ¹»·Î ³ÖÀ¸½Ã´ÂÁö ±Ã±ÝÇÕ´Ï´Ù. ±×¸®°í, À¯¾ÏÁ¾ G2~3À¸·Î grade°¡ ¿Ã¶ó°¡¸é »êÁ¤Æ¯·Ê·Î ÇؾßÇÏ´ÂÁöµµ ±Ã±ÝÇÕ´Ï´Ù.

À§ À¯¾ÏÁ¾Àº f/u¿¡ ´ëÇؼ­ ÀÚ¼¼ÇÑ µµÇ¥°¡ ÀÖ¾ú´Âµ¥ EndoTODAY¿¡¼­ Á÷Àå À¯¾ÏÁ¾¿¡ ´ëÇؼ­´Â f/u ¿¡ ´ëÇÑ µµÇ¥°¡ ¾ø¾î¼­¿ä. À§¶û °°ÀÌ Ã³¸®ÇÏ¸é µÇ´ÂÁö¿ä? ¼±»ý´Ô ±âÀçÇϽŠ³»¿ëº¸¸é °£È¤ f/u¿¡¼­ ÀüÀÌ°¡ ÀÖ´Ù°í Çϼ̴µ¥, ´ëºÎºÐÀÌ ±¦Âú´Ù°í ÇϽñä Çϼ̽À´Ï´Ù.

ÀÌÁ¦ ¼±¼±ÇØÁö´Âµ¥ ȯÀý±â¿¡ °¨±â Á¶½ÉÇϽðí¿ä, ¸Ó³ª¸Õ ½Ã°ñ¿¡¼­ ¼±»ý´Ô ´öºÐ¿¡ ȯÀÚµéÇÑÅ× ¼±»ý´Ô °æÇèÀ» Á¶±ÝÀÌ¶óµµ ºô·Á Á» ´õ Àß Áø·áÇÒ ¼ö ÀÖ´Ù´Â »ç½Ç¿¡ Ç×»ó °¨»çµå¸³´Ï´Ù.

[2017-9-1. ÀÌÁØÇà ´äº¯]

ÀÏÀü¿¡ Á¦°¡ ¾Æ·¡¿Í °°Àº position statement¸¦ ³½ ÀûÀÌ Àִµ¥ ¾ÆÁ÷µµ °°Àº ÀÔÀåÀÔ´Ï´Ù.

[Position statement. 2016-9-4. ÀÌÁØÇà] Á÷Àå À¯¾ÏÁ¾ ÄÚµå´Â ¾ÆÁ÷ Çй®ÀûÀ¸·Î Á¤¸³µÇÁö ¾ÊÀº ºÎºÐÀÔ´Ï´Ù. ÇöÀç·Î¼­´Â ´ëÀå³»½Ã°æ Àü¹®°¡µéÀÇ ÀÇ°ß(¾Æ·¡ µµÇ¥)À» µû¸£´Â °ÍÀÌ °¡Àå ÀûÀýÇÒ °ÍÀ¸·Î ÆǴܵ˴ϴÙ.

Clin Endosc 2015

ÄÚµå´Â Á¤ºÎ°¡ Ã¥ÀÓÀ» ¹æ±â(ۯѥ; ³õÀ» ¹æ, ¹ö¸± ±â)ÇÏ°í ÀÖ´Â ºÎºÐÀÎÁö¶ó, Áï Á¤È®ÇÑ ±âÁØÀ» ¹àÈ÷Áö ¾Ê°í ÀÖ´ÂÁö¶ó ¾î´À ´©±¸µµ ´äÇÒ ¼ö ¾ø´Â ¿µ¿ªÀÔ´Ï´Ù. ¾Æ·¡¸¦ ÂüÁ¶Çϼ¼¿ä.

* Âü°í: EndoTODAY ÄÚµå


[2017-9-2. ¾Öµ¶ÀÚ ÆíÁö]

1cm ¹Ì¸¸ÀÇ Rectal NET¿¡´ëÇØ DÄÚµåÀÎÁö CÄÚµåÀÎÁö´Â Àü¹®°¡ ÀÇ°ß¿¡ µû¶ó¾ß°ÚÁö¸¸ ¾ÆÁ÷ È¥¶õ½º·´½À´Ï´Ù. ƯÈ÷ 'DÄڵ带 ÁÖ´Â ÀÇ»ç°áÁ¤'°ú '(¸Å¿ì ³·Áö¸¸) ÀüÀÌ °¡´É¼ºÀ» È®ÀÎÇϱâÀ§ÇØ º¹ºÎCT¸¦ ÃÔ¿µÇÏ´Â ÀÇ»ç°áÁ¤'Àº ÀÌÀ²¹è¹ÝÀûÀÎ ÀÇ»ç°áÁ¤À̶ó°í »ý°¢µË´Ï´Ù.

[2017-9-2. ÀÌÁØÇà ´äº¯]

ÁÁÀº ÀÇ°ß °¨»çÇÕ´Ï´Ù. 'Àü¹®°¡ ÀÇ°ßÀ» µû¸£´Â °Í'Àº ÀÏ°ß ½¬¿î ÀÏ °°Áö¸¸ (1) Àü¹®°¡µé¸¶´Ù ÀÇ°ßÀÌ ´Ù¸¥ °æ¿ì°¡ ¸¹°í, (2) Àü¹®°¡µé ¸ðÀÓ¿¡¼­ °¡À̵å¶óÀÎÀ̳ª consensus º¸°í¼­¸¦ ³»°í ÀÖÀ¸³ª, ¿©·¯ ´Ù¸¥ ±×·ì¿¡¼­ ¾à°£¾¿ ´Ù¸¥ º¸°í¼­¸¦ ³»°í À־ ¾î´À °ÍÀ» Ç¥ÁØÀ¸·Î ÇÒ °ÍÀÎÁö ¾Ë ¼ö ¾øÀ¸¸ç, (3) °°Àº ±×·ì¿¡¼­µµ ºñ½ÁÇÑ º¸°í¼­ÀÇ update versionÀ» ³»°ï Çϴµ¥ ±×¶§¸¶´Ù ÄÚµå¿Í ºñ¿ëÀÌ ´Þ¶ó¾ß ÇÏ´ÂÁö µî ½±Áö ¾ÊÀº À̽´°¡ ¸¹½À´Ï´Ù. µû¶ó¼­ ÀÌ°ÍÀº Ä®ÀÚ·ç ȤÀº µ·Àڷ縦 Áã°í ÀÖ´Â Á¤ºÎ¿¡¼­ (1) Á÷Á¢ Á¤È®ÇÑ ÄÚµå ÁöħÀ» ³»¸®°Å³ª (2) ¾î´À ÇÐȸ¿¡¼­ ¾ðÁ¦ ¹ßÇ¥ÇÑ consensus º¸°í¼­¸¦ µû¸¥´Ù°í Á¤ÇØ ÁÖÁö ¾Ê´Â ÇÑ È¥¼±Àº °è¼ÓµÉ ¼ö ¹Û¿¡ ¾ø´Â ±¸Á¶ÀÔ´Ï´Ù. ±¹¹ÎÀÇ ÀÇ·áºñ¿ë ºÎ´ãÀ» ÁÙÀÌ´Â °ÍÀº ÁÁÀº Á¤Ã¥¹æÇâÀÌÁö¸¸, Äڵ峪 Áø´Ü¸í¿¡ µû¶ó¼­ ¼¼¼¼ÇÑ ºñ¿ë Çϳª Çϳª¸¦ ±ð¾ÆÁÖ´Â Á¤Ã¥Àº È¥¼±ÀÌ ¸¹°í °úÀ× Áø·á¸¦ À¯¹ßÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Ù°í »ý°¢ÇÕ´Ï´Ù. CT´Â ÀüÀÌ °¡´É¼ºÀÌ ¸Å¿ì¸Å¿ì ³·¾Æµµ Âï¾îº¼ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù.


[2019-12-6. ¾Öµ¶ÀÚ Áú¹®]

±³¼ö´Ô. Rectal carcinoid °°Àº°æ¿ì 5~10mm Á¤µµ·Î ÀÛ°Ô ¹ß°ßµÇ´Â °æ¿ì°¡ Àִµ¥ »ó±Þº´¿ø ÀǷڽà bx¸¦ Çϴ°ÍÀÌ ÁÁÀ»½Ã ¾Æ´Ï¸é NET °¡ À°¾ÈÀ¸·Î ÀÇ½ÉµÇ¸é ±×´ë·Î ³öµÎ°í ÀǷڵ帮´Â°ÍÀÌ ÁÁÀ»Áö ±Ã±ÝÇÕ´Ï´Ù. mailgnant potential ÀÌ À־ÀÌ´Â º´º¯À» 1Â÷ÀÇ·á±â°ü¿¡¼­ EMR À» Çϱ⿡´Â ºÎ´ãµµ µÇ¼­¿ä..

[2019-12-6. ÀÌÁØÇà ´äº¯]

Rectal carcinoid ó·³ º¸ÀÌ´Â º´º¯À» Á¶Á÷°Ë»ç ¾øÀÌ ¹Ù·Î EMR/ESD ÇÏ´Â °æ¿ì´Â µå¹° °Í °°½À´Ï´Ù. 1Â÷ ÀÇ·á±â°ü¿¡¼­ Á¶Á÷°Ë»ç ÈÄ ÀÇ·ÚÁֽøé ÁßÁõÁ¾ÇÕº´¿ø¿¡¼­´Â ´Ù¾çÇÑ ³»½Ã°æÀû ¹æ¹ýÀ¸·Î Á¦°ÅÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. Âü°í·Î carcinoid´Â Á¡¸·ÇÏÁ¾¾çÀ̶ó´Â ³ÐÀº ¹üÁÖ¿¡ ¼ÓÇØÀÖÁö¸¸ ÁÖ·Î lamina propria ±â¿øÀÔ´Ï´Ù. ½ÇÁ¦·Î forceps biopsy¸¦ ÅëÇÏ¿© Á¶Á÷ÇÐÀû Áø´ÜÀÌ Àß µÇ´Â ÆíÀÔ´Ï´Ù.


[References]

1) EndoTODAY Gastric carcinoid À§À¯¾ÏÁ¾

2) EndoTODAY Duodenal carcinoid ½ÊÀÌÁöÀå À¯¾ÏÁ¾

3) EndoTODAY Colorectal neuroendocrine tumor. carcinoid °áÀåÁ÷Àå ½Å°æ³»ºÐºñÁ¾¾ç. Á÷Àå À¯¾ÏÁ¾.

4) Carcinoid Tumor ´ëÇÑ Helicobacter ¹× »óºÎÀ§Àå°ü ¿¬±¸ÇÐȸ Ãá°è½ÉÆ÷Áö¾ö (ÀÌÁØÇà. 2009)

5) EndoTODAY Case: rectal carcinoid with metastasis Á÷Àå À¯¾ÏÁ¾ ¸²ÇÁÀý ÀüÀÌ Áõ·Ê

6) Á÷Àå ½Å°æ³»ºÐºñÁ¾¾ç rectal neuroendocrine tumor ÀÇ Áø´Ü°ú Ä¡·á 2022-2-22 Á¦1ȸ KSGE Webinar º¯Á¤½Ä ±³¼ö´Ô (log-in required) - Q and A



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.